Biotech · Private company
Oblato, Inc.
Track this companyFree. Adds Oblato, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- OKN-007Phase 2 · Recurrent Malignant GliomaClinicalTrials.gov · fetched Nov 12, 2026
- Temozolomide (TMZ)Phase 2 · Recurrent Malignant GliomaClinicalTrials.gov · fetched Nov 12, 2026
- High-dose OKN-007, TIDPhase 1 · High-grade GliomaClinicalTrials.gov · fetched Nov 12, 2026
- Low-dose OKN-007, BIDPhase 1 · High-grade GliomaClinicalTrials.gov · fetched Nov 12, 2026
- Low-dose OKN-007, TIDPhase 1 · High-grade GliomaClinicalTrials.gov · fetched Nov 12, 2026
- Mid-dose OKN-007, TIDPhase 1 · High-grade GliomaClinicalTrials.gov · fetched Nov 12, 2026
- OKN-007Diffuse Midline Glioma, H3 K27M-MutantClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade GliomaPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 17, 2023ClinicalTrials.gov NCT05561374 · fetched Nov 12, 2026
- Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent GlioblastomaPHASE2 · COMPLETED · started Jun 12, 2020ClinicalTrials.gov NCT04388475 · fetched Nov 12, 2026
- Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma PatientsPHASE1 · UNKNOWN · started Dec 1, 2012ClinicalTrials.gov NCT01672463 · fetched Nov 12, 2026
- Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-alteredNO_LONGER_AVAILABLEClinicalTrials.gov NCT05518838 · fetched Nov 12, 2026